Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas
- Conditions
- Pneumonia
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 978
- Registration Number
- NCT00538018
AMS VS MOXI Ketek vs Avelox in AMS
- Conditions
- Maxillary Sinusitis
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 351
- Registration Number
- NCT00537563
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2007-10-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 80
- Registration Number
- NCT00537251
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 55
- Registration Number
- NCT00535340
- Locations
- 🇸🇰
Sanofi-Aventis Administrative Office, Bratislava, Slovakia
Venous Thromboembolism Taskforce Audit Program
- Conditions
- Venous Thrombosis
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2010-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8764
- Registration Number
- NCT00535171
- Locations
- 🇦🇺
Sanofi-Aventis, MacQuarie Park, Australia
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
- Conditions
- CarcinomaNon Small Cell Lung
- Interventions
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 913
- Registration Number
- NCT00532155
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Taipei, Taiwan
🇹🇷Sanofi-Aventis Administraive Office, Istanbul, Turkey
🇬🇧Sanofi-Aventis Admnistrative Office, Guildford Surrey, United Kingdom
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 643
- Registration Number
- NCT00531622
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
Insomnia and Daytime Function in Osteoarthritis
- Conditions
- Sleep Disorders
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 170
- Registration Number
- NCT00530556
Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 108
- Registration Number
- NCT00529750
Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 188
- Registration Number
- NCT00526513
- Locations
- 🇪🇬
Sanofi-Aventis Administrative Office, Cairo, Egypt